Home/MapLight Therapeutics/Anatol Kreitzer
AK

Anatol Kreitzer

Chief Discovery Officer

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Schizophrenia (negative symptoms)Phase 2
ML-004Autism Spectrum Disorder (ASD)Phase 1
UndisclosedParkinson's DiseasePreclinical